Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Inhibikase Therapeutics

12/08/2026 13:01

Inhibikase Therapeutics, Inc. IKT.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of eight analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -15 cents to -8 cents per share.
Reported revenue was zero​; analysts expected zero. 
Inhibikase Therapeutics, Inc.'s reported EPS for the quarter was a loss of 11 cents​.
The company reported a quarterly loss of $19.59 million.
Inhibikase Therapeutics, Inc. shares had risen by 20.7% this quarter and gained 19.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Inhibikase Therapeutics, Inc. is $6.00, about 59.2% above its last closing price of $2.45
This summary was machine generated from LSEG data August 12 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.11
-0.11
Met
Mar. 31 2026 
-0.11
-0.10
Beat
Dec. 31 2025 
-0.10
-0.09
Beat
Sep. 30 2025 
-0.13
-0.13
Met